Navigation Links
UltraPure™ Agarose

ProductsUltraPure™ Agarose
Company Invitrogen
Item UltraPure™ Agarose
Features 
Description UltraPure™ Agarose resolves DNA and RNA fragments from 100 bp to >30 kb. UltraPure™ Agarose is a standard melting temperature multi-purpose agarose that is ideal for routine separation analysis. Its high gel strength specification ensures that gels will not break during handling nor during Southern and Northern transfers. UltraPure™ Agarose can also be used in some protein electrophoresis applications such as Ouchterlony (antigen-antibody interaction assay) and radial immunodiffusion (RID) (antigen quantitation assay).UltraPure™ Agarose can be used in:- -Analytical separation of DNA RNA and PCR fragments >1000 bp- Recovery of DNA RNA and PCR fragments >1000 bp- Southern and Northern blotting of fragments >1000 bp-Ouchterlony and radial immunodiffusion (RID)
Info Invitrogen
Customer Service: (760) 603-7200
Web site: http://www.invitrogen.com

Related medicine products :

1. UltraPure™ Agarose 1000
2. LB Top Agarose 100ml Bottle
3. LB Agarose Plates
4. Agarose-HR™
5. Agarose for the Separation of GeneAmp® PCR Products
6. Certified PCR Agarose
7. Certified Molecular Biology Agarose
8. Certified Low Range Ultra Agarose
9. Certified Megabase Agarose
10. Agarose, Type C
11. SeaKem® GTG® Agarose
Breaking Medicine News(10 mins):Health News:Unanimous Vote Creates Largest RN Union in U.S. History 2Health News:Senator Ben Nelson Puts U.S. Bishops' Interests Ahead of Americans' Healthcare Needs 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5Health News:Pitt study suggests craving hinders comprehension without your realizing it 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 3Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 4Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 5
Other Medicine News:Health News:New Employee of the Nations Largest Healthcare Consulting Firm 2Health News:Rochester study raises new questions about controversial plastics chemical 2Health News:Rochester study raises new questions about controversial plastics chemical 3Health News:Courage Center Experts Disagree With Gov. Pawlenty's Proposed Budget Cuts 2Health News:Courage Center Experts Disagree With Gov. Pawlenty's Proposed Budget Cuts 3Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 2Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 3Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 2Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 3Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 4Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 5Health News:C8 Science Panel Completes Uric Acid Study 2
Breaking Medicine Technology:Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 2Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 3Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Sigma Aldrich 28R 29 and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement 14347 1Sigma Aldrich 28R 29 and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement 14347 2Sigma Aldrich 28R 29 and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement 14347 3Sigma Aldrich 28R 29 and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement 14347 4Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development 5206 1Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development 5206 2Frost 26amp 3B Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 5205 1Frost 26amp 3B Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 5205 2Frost 26amp 3B Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 5205 3Frost 26amp 3B Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 5205 4